Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant protein + Advax
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
recombinant protein + Advax refers to a vaccine platform developed by Vaxine that combines recombinant protein antigens with the proprietary Advax adjuvant. Advax is a non-inflammatory adjuvant derived from delta-inulin designed to enhance both humoral and cellular immune responses, specifically targeting Th1 and Th17 pathways which are critical for protection against intracellular pathogens. This platform is applied to several candidates in Vaxine's pipeline, most notably a tuberculosis vaccine (currently in IND-enabling studies) targeting Mycobacterium tuberculosis antigens, and an Alzheimer's disease vaccine (in Phase 1) targeting amyloid and tau proteins. Other preclinical applications include vaccines for Shigellosis and Zika virus infection. The platform is intended to provide robust immunogenicity without the high reactogenicity often associated with traditional adjuvants.
- Other names
- recombinant protein + Advax TB vaccinerecombinant protein + Advax Shigella vaccinerecombinant protein + Advax Alzheimer's vaccinerecombinant protein + Advax Zika vaccine
02
Targets
Aβ (Amyloid-beta pathological forms)pE-Aβ (Pyroglutamylated amyloid-β)TLR9 (Toll-like receptor 9)4R tau (Microtubule-associated protein tau (cis-pT231 conformation))ZIKV E (Zika virus envelope protein)S. flexneri LPS (Shigella flexneri lipopolysaccharide)Shigella sonnei O-specific polysaccharide
Beyond the preview
Go deeper on recombinant protein + Advax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant protein + Advax.